XML 47 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Disaggregation of Revenue        
Total revenues $ 41,531 $ 26,366 $ 72,509 $ 70,345
Royalties        
Disaggregation of Revenue        
Total revenues 23,162 20,938 42,257 38,585
Revenue from intangible royalty assets        
Disaggregation of Revenue        
Total revenues 22,603 20,430 40,960 37,584
Kyprolis        
Disaggregation of Revenue        
Total revenues 8,998 8,097 15,630 14,325
Evomela        
Disaggregation of Revenue        
Total revenues 2,733 2,357 4,130 4,907
Teriparatide injection        
Disaggregation of Revenue        
Total revenues 2,103 3,613 4,144 7,113
Rylaze        
Disaggregation of Revenue        
Total revenues 3,232 3,028 6,184 5,637
Filspari        
Disaggregation of Revenue        
Total revenues 2,424 315 4,196 585
Vaxneuvance        
Disaggregation of Revenue        
Total revenues 1,109 1,039 2,496 1,677
Other        
Disaggregation of Revenue        
Total revenues 2,004 1,981 4,180 3,340
Income from financial royalty assets        
Disaggregation of Revenue        
Total revenues 559 508 1,297 1,001
Captisol        
Disaggregation of Revenue        
Total revenues 7,500 5,220 16,712 15,842
Contract revenue and other income        
Disaggregation of Revenue        
Total revenues 10,869 208 13,540 15,918
Milestone and other        
Disaggregation of Revenue        
Total revenues 10,869 208 11,596 15,918
Other income        
Disaggregation of Revenue        
Total revenues $ 0 $ 0 $ 1,944 $ 0